UBS AM
ROIV icon

UBS AM’s Roivant Sciences ROIV Stock Holding History

UBS AM’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$588K Sell
16,627
-1,724,853
-99% -$51M ﹤0.01% 2500
2026
Q1 		$48.2M Sell
1,741,480
-343,129
-16% -$8.81M 0.01% 634
2025
Q4 		$45.2M Sell
2,084,609
-39,008
-2% -$770K 0.01% 629
2025
Q3 		$32.1M Sell
2,123,617
-651,732
-23% -$8.07M 0.01% 687
2025
Q2 		$31.3M Buy
2,775,349
+329,542
+13% +$3.57M 0.01% 867
2025
Q1 		$24.7M Buy
2,445,807
+34,341
+1% +$371K 0.01% 875
2024
Q4 		$28.5M Buy
2,411,466
+104,288
+5% +$1.23M 0.01% 819
2024
Q3 		$26.6M Buy
2,307,178
+762,953
+49% +$8.69M 0.01% 843
2024
Q2 		$16.3M Buy
1,544,225
+399,797
+35% +$4.38M ﹤0.01% 937
2024
Q1 		$12.1M Sell
1,144,428
-2,204
-0.2% -$23.8K ﹤0.01% 938
2023
Q4 		$12.9M Buy
1,146,632
+97,432
+9% +$950K 0.01% 905
2023
Q3 		$12.3M Buy
1,049,200
+749,191
+250% +$8.47M 0.01% 888
2023
Q2 		$2.21M Hold
300,009
– – ﹤0.01% 1596
2023
Q1 		$2.21M Sell
300,009
-26,033
-8% -$214K ﹤0.01% 1596
2022
Q4 		$2.61M Buy
326,042
+53,493
+20% +$298K ﹤0.01% 1413
2022
Q3 		$878K Buy
272,549
+35,783
+15% +$139K ﹤0.01% 2041
2022
Q2 		$964K Buy
+236,766
New +$940K ﹤0.01% 1986

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

UBS AM's ROIV Position: Q2 2026 in Review

UBS AM reduced its Roivant Sciences (ROIV) stake by 99% in Q2 2026, selling an estimated $51M and leaving 16,627 shares worth $588K. The position accounts for ﹤0.01% of the portfolio, ranked #2500.

UBS AM first reported a position in ROIV in Q2 2022 and has held it in 17 quarters since. The position peaked at $48.2M in Q1 2026. 496 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • UBS AM held 16,627 shares of Roivant Sciences worth $588K as of Q2 2026.
  • UBS AM sold 1,724,853 Roivant Sciences shares in Q2 2026, an estimated $51M.
  • Roivant Sciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2500 holding.
  • UBS AM first reported a position in Roivant Sciences in Q2 2022 and has held it in 17 quarters since.
  • UBS AM's Roivant Sciences position peaked at $48.2M in Q1 2026.
  • 496 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.